微囊化药物递送：一种抑制促炎细胞因子的新方法。
Microencapsulated drug delivery: a new approach to pro-inflammatory cytokine inhibition.
机构信息
College of Pharmacy and Health Sciences, Mercer University, 3001 Mercer University Drive, Atlanta, GA 30341, USA.
出版信息
J Microencapsul. 2012;29(5):455-62. doi: 10.3109/02652048.2012.658443. Epub 2012 Feb 21.
CONTEXT
This article reviews the use of albumin microcapsules 3-4 µm in size containing cytokine inhibiting drugs which include neutralizing antibodies to TNF and IL1, CNI-1493, antisense oligonucleotides to TNF and NF-kappaB, and the antioxidant catalase.
OBJECTIVE
Describe the effects, cellular uptake and distribution of microencapsulated drugs and the effect in both a peritonitis model of infection and a model of adjuvant-induced arthritis.
METHODS
The studies performed by our group are reviewed, the only such studies available.
RESULTS
Microencapsulation of these compounds produced high intracellular drug concentrations due to rapid uptake by phagocytic cells, including endothelial cells, without toxicity. All compounds produced excellent inhibition of TNF and IL1 resulting in improved animal survival in a peritonitis model of septic shock and inflammation in an arthritis model.
CONCLUSION
Albumin microencapsulated pro-inflammatory cytokine inhibiting compounds are superior to equivalent concentration of these compounds administered in solution form.
背景
本文综述了使用 3-4µm 大小的白蛋白微囊来包裹细胞因子抑制药物，包括针对 TNF 和 IL1 的中和抗体、CNI-1493、针对 TNF 和 NF-κB 的反义寡核苷酸，以及抗氧化剂过氧化氢酶。
目的
描述载药微囊的作用、细胞摄取和分布，以及在感染性腹膜炎模型和佐剂性关节炎模型中的作用。
方法
我们小组进行的研究被回顾，这是唯一的此类研究。
结果
这些化合物的微囊化由于吞噬细胞（包括内皮细胞）的快速摄取而产生了高细胞内药物浓度，而没有毒性。所有化合物均能极好地抑制 TNF 和 IL1，从而提高了腹膜炎性休克模型中动物的存活率，并改善了关节炎模型中的炎症。
结论
载有促炎细胞因子抑制化合物的白蛋白微囊优于以溶液形式给予相同浓度的这些化合物。
Zotero 插件